Sacituzumab govitecan, an antibody-drug conjugate targeting Trophoblast cell surface antigen 2 (Trop-2), demonstrated remarkable efficacy in treating metastatic triple-negative breast cancer. This evidence concerns the gene TACSTD2 and triple-negative breast carcinoma.